Get the Stockscreener App
2.10
0.96%
0.02
After Hours:
2.10
Metagenomi Inc stock is traded at $2.10, with a volume of 703.79K.
It is up +0.96% in the last 24 hours and up +45.83% over the past month.
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
See More
Previous Close:
$2.08
Open:
$2.11
24h Volume:
703.79K
Relative Volume:
1.31
Market Cap:
$78.50M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-9.87%
1M Performance:
+45.83%
6M Performance:
-24.19%
1Y Performance:
-60.00%
1-Day Range:
$2.07
$2.25
1-Week Range:
$2.04
$2.40
52-Week Range:
$1.23
$5.38
Metagenomi Inc Stock (MGX) Company Profile
Name
Metagenomi Inc
Sector
Industry
Phone
(510) 871-4880
Address
5959 HORTON STREET, EMERYVILLE
Compare MGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGX
Metagenomi Inc
|
2.10 | 71.40M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.40 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.92 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
279.77 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Metagenomi Inc Stock (MGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Initiated | H.C. Wainwright | Buy |
| May-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-05-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-24 | Initiated | Chardan Capital Markets | Buy |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Mar-05-24 | Initiated | Jefferies | Buy |
| Mar-05-24 | Initiated | TD Cowen | Outperform |
| Mar-05-24 | Initiated | Wells Fargo | Overweight |
View All
Metagenomi Inc Stock (MGX) Latest News
why metagenomi inc. stock attracts strong analyst attentionFree Stock Trading Signals - Newser
Why Metagenomi Inc. stock attracts strong analyst attentionTargeted 200 Percent Gain - Newser
How Metagenomi Inc. stock performs during market volatilityDouble Your Capital Alerts - Newser
What makes Metagenomi Inc. stock price move sharplyDaily Price Surge List - Newser
Metagenomi Showcases Advanced AI-Enhanced Gene Editing for Neurological Disorders at ASGCT Meeting - Insider Monkey
12 Best Young Stocks To Buy and Hold For 5 Years - Insider Monkey
Metagenomi, Inc. shares fall 1.29% in after-hours trading following positive market report and collaboration updates. - AInvest
Metagenomi, Inc.(NasdaqGS: MGX) dropped from Russell 2500 Index - MarketScreener
Critical Survey: Guardian Pharmacy Services (NYSE:GRDN) & Metagenomi (NASDAQ:MGX) - Defense World
Sam Altman Says He 'Didn't Think' Elon Musk Would Abuse Government Power, Tesla CEO Hits Back With 'Scam Altman' JibeOracle (NYSE:ORCL), Metagenomi (NASDAQ:MGX) - Benzinga
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Metagenomi Requests to Dismiss Class Action Filed by Investors - TradingView
Metagenomi, Inc. (NASDAQ:MGX) Shares Sold by Millennium Management LLC - Defense World
Two Sigma Investments LP Sells 59,135 Shares of Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Metagenomi CEO Thomas Brian sells shares worth $18,873 By Investing.com - Investing.com India
Metagenomi CEO Thomas Brian sells shares worth $18,873 - Investing.com
Metagenomi Executives Sell Shares to Cover Tax Obligations - TradingView
Metagenomi Director Irish Jian Sells Shares to Cover Tax Obligations - TradingView
Jane Street Group LLC Invests $107,000 in Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Nuveen Asset Management LLC Buys Shares of 63,248 Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Metagenomi Being Investigated on Behalf of Metagenomi, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
Adverum Biotechnologies (NASDAQ:ADVM) versus Metagenomi (NASDAQ:MGX) Head-To-Head Analysis - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 11,730 Shares of Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Metagenomi, Inc. (NASDAQ:MGX) Short Interest Down 18.9% in May - Defense World
Citadel Advisors LLC Decreases Position in Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Northern Trust Corp Raises Position in Metagenomi, Inc. (NASDAQ:MGX) - Defense World
What is HC Wainwright’s Forecast for Metagenomi Q2 Earnings? - Defense World
Equities Analysts Issue Forecasts for Metagenomi Q1 Earnings - Defense World
Metagenomi Inc (NASDAQ: MGX): Finding Hidden Gems Among Volatility - Stocksregister
MGX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Metagenomi, Inc. investment - ACCESS Newswire
Price T Rowe Associates Inc. MD Buys New Holdings in Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Chardan Capital Has Lowered Expectations for Metagenomi (NASDAQ:MGX) Stock Price - Defense World
Metagenomi, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance
Voya Investment Management LLC Acquires Shares of 10,314 Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Demystifying Metagenomi: Insights From 4 Analyst Reviews - Benzinga
Chardan Cuts Price Target on Metagenomi to $12 From $13, Keeps Buy Rating - marketscreener.com
Metagenomi, Inc. (NASDAQ:MGX) Shares Bought by Barclays PLC - Defense World
Metagenomi price target lowered to $16 from $20 at Wells Fargo - TipRanks
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing ... - Bluefield Daily Telegraph
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025 - Yahoo Finance
Metagenomi Presents Data Highlighting Advancements in - GlobeNewswire
Metagenomi (MGX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Metagenomi: Q1 Earnings Snapshot - San Francisco Chronicle
Metagenomi reports Q1 EPS (68c), consensus (51c) - TipRanks
Metagenomi Reports Positive NHP Study Results for Hemophilia A Program and Quarterly Financials - Nasdaq
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results - The Manila Times
Metagenomi Q1 Earnings: Breakthrough Hemophilia Treatment Maintains 75% Effectiveness After 19 Months - Stock Titan
Metagenomi Inc Stock (MGX) Financials Data
There is no financial data for Metagenomi Inc (MGX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Metagenomi Inc Stock (MGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wein Matthew | See Remarks |
Jun 06 '25 |
Sale |
1.75 |
199 |
348 |
16,693 |
| Noonberg Sarah B. | Chief Medical Officer |
Jun 06 '25 |
Sale |
1.75 |
5,239 |
9,168 |
109,135 |
| Wapnick Pamela | Chief Financial Officer |
Jun 06 '25 |
Sale |
1.75 |
1,576 |
2,758 |
72,108 |
| Thomas Brian C. | Chief Executive Officer |
Jun 06 '25 |
Sale |
1.75 |
10,785 |
18,874 |
2,517,491 |
| Irish Jian | See Remarks |
Jun 06 '25 |
Sale |
1.75 |
6,390 |
11,182 |
315,543 |
| Wein Matthew | See Remarks |
Mar 05 '25 |
Sale |
1.87 |
930 |
1,744 |
9,467 |
| Wapnick Pamela | Chief Financial Officer |
Mar 05 '25 |
Sale |
1.87 |
1,808 |
3,390 |
59,684 |
| Wapnick Pamela | Chief Financial Officer |
Dec 05 '24 |
Sale |
1.86 |
1,559 |
2,900 |
61,492 |
| Wapnick Pamela | Chief Financial Officer |
Sep 05 '24 |
Sale |
2.88 |
6,265 |
18,043 |
63,051 |
3.38%
2.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):